Therapeutic and prophylactic applications of bacteriophage components in modern medicine

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 1, 2014, Pages

  Adhya, Sankar ^a   Merril, Carl R ^b   Biswas, Biswajit ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOPHAGE DNA; LYSOZYME; PHAGE DISPLAY VACCINE; PHAGE DNA VACCINE; UNCLASSIFIED DRUG; VACCINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE; BREWING; COLIPHAGE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; INFECTION; INFLAMMATION; NONHUMAN; PHAGE DISPLAY; PLANT CELL CULTURE; VACCINATION; ANIMAL; BACTERIAL INFECTION; DISEASE MODEL; HUMAN; IMMUNOLOGY; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIOPHAGES; DISEASE MODELS, ANIMAL; HUMANS; MURAMIDASE; VACCINES;

EID: 84891813916     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a012518     Document Type: Article

References (81)

1. Alisky J., Iczkowski K, Rapoport A, Troitsky N. 1998. Bacteriophages show promise as antimicrobial agents. J Infect 36: 5-15.
2. Baba T., Schneewind O. 1998. Instruments of microbial warfare: Bacteriocin synthesis, toxicity and immunity. Trends Microbiol 6: 66-71.
3. Barrett A.D.T., Stanberry LR. 2008. Vaccines for biodefence and emerging and neglected diseases. Academic, Waltham, MA.
4. Benhar I. 2001. Biotechnological applications of phage and cell display. Biotechnol Adv 19: 1-33.
5. Biswas B., Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R., Merril CR. 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 70: 204-210.
6. Bull J.J., Levin BR, DeRouin T, Walker N, Bloch CA. 2002. Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol 2: 35.
7. Burdin N., Guy B, Moingeon P. 2004. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs 18: 79-93.
8. Carlton RM. 1999. Phage therapy: Past history and future prospects. Arch Immunol Ther Exp 47: 267-274.
9. Clark J.R., March JB. 2004a. Bacterial viruses as human vaccines? Expert Rev Vaccines 3: 463-476.
10. Clark JR, March JB. 2004b. Bacteriophage-mediated nucleic acid immunisation. FEMS Immunol Med Microbiol 40: 21-26.
11. Clark J.R., March JB. 2006. Bacteriophages and biotechnology: Vaccines, gene therapy and antibacterials. Trends Biotechnol 24: 212-218.
12. Daeschel M.A., Jung DS, Watson BT. 1991. Controlling wine malolactic fermentation with nisin and nisin-resistant strains of Leuconostoc oenos. Appl Environ Microbiol 57: 601-603.
13. Delbruck M. 1940. The growth of bacteriophage and lysis of the host. J Gen Physiol 23: 643-660.
14. Delmastro P., Meola A, Monaci P, Cortese R, Galfre G. 1997. Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration. Vaccine 15: 1276-1285.
15. Dubos R.J., Straus JH, Pierce C. 1943. The multiplication of bacteriophage in vivo and its protective effect against an experimental infection with Shigella dysenteriae. J Exp Med 78: 161-168.
16. Fang J, Wang G, Yang Q, Song J, Wang Y, Wang L. 2005. The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model. Vaccine 23: 4860-4866.
17. Feeney R.E., Nagy DA. 1952. The antibacterial activity of the egg white protein conalbumin. J Bacteriol 64: 629-643.
18. Fischetti VA. 2010. Bacteriophage endolysins: A novel antiinfective to control Gram-positive pathogens. Int J Med Microbiol 300: 357-362.
19. Fleming A. 1922. On a remarkable bacteriolytic element found in tissues and secretions. P Roy Soc London B 93: 306-317.
20. Frenkel D., Katz O, Solomon B. 2000. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc Natl Acad Sci 97: 11455-11459.
21. Gaubin M., Fanutti C, Mishal Z, Durrbach A, De Berardinis P, Sartorius R, Del Pozzo G, Guardiola J, Perham RN, Piatier-Tonneau D. 2003. Processing of filamentous bacteriophage virions in antigen-presenting cells targets both HLA class I and class II peptide loading compartments. DNA Cell Biol 22: 11-18.
22. Gu J, Liu X, Li Y, HanW, Lei L, Yang Y, Zhao H, Gao Y, Song J, Lu R., et al. 2012. A method for generation phage cocktail with great therapeutic potential. PloS ONE 7: e31698.
23. Gupta A., Onda M, Pastan I, Adhya S, Chaudhary VK. 2003. High-density functional display of proteins on bacteriophage λ. J Mol Biol 334: 241-254.
24. Hayes S., Gamage LN, Hayes C. 2010. Dual expression system for assembling phage λ display particle (LDP) vaccine to porcine Circovirus 2 (PCV2). Vaccine 28: 6789-6799.
25. Horst J., Kluge JF, Beyreuther K, GerokW. 1975. Gene transfer to human cells: Transducing phage λ plac gene expression in GM1-gangliosidosis fibroblasts. Proc Natl Acad Sci 72: 3531-3535.
26. Iwasaki K., Trus BL, Wingfield PT, Cheng N, Campusano G, Rao V.B., Steven AC. 2000. Molecular architecture of bacteriophage T4 capsid:Vertex structure and bimodal binding of the stabilizing accessory protein, Soc. Virology 271: 321-333.
27. Jernberg C., Lofmark S, Edlund C, Jansson JK. 2010. Longterm impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 156: 3216-3223.
28. Jervis E.J., Guarna MM, Doheny JG, Haynes CA, Kilburn DG. 2005. Dynamic localization and persistent stimulation of factor-dependent cells by a stem cell factor/cellulose binding domain fusion protein. Biotechnol Bioeng 91: 314-324.
29. Jiang J., AbuShilbayeh L, Rao VB. 1997. Display of a PorA peptide from Neisseria meningitidis on the bacteriophage T4 capsid surface. Infect Immun 65: 4770-4777.
30. Krieg A.M., Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R., Koretzky GA, Klinman DM. 1995. Cpg motifs in bacterial-DNA trigger direct B-cell activation. Nature 374: 546-549.
31. Lacroix B., Tzfira T, Vainstein A, Citovsky V. 2006. A case of promiscuity: Agrobacterium's endless hunt for new partners. Trends Genet 22: 29-37.
32. Landschoot AV. 2005. Antibacterial properties of hen egg white lysozyme against beer spoilage bacteria and effect of lysozyme on yeast fermentation. Cerevisia 32: 219-225.
33. Larson AE. 2005. Lysozyme in antimicrobial in food. Taylor and Francis, London.
34. Li Q., Shivachandra SB, Leppla SH, Rao VB. 2006a. Bacteriophage T4 capsid:Aunique platform for efficient surface assembly of macromolecular complexes. J Mol Biol 363: 577-588.
35. Li X.H., Tang L, Liu D, Sun HM, Zhou CC, Tan LS, Wang LP, Zhang P.D., Zhang SQ. 2006b. Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice. Ai Zheng 25: 1221-1226.
36. Li Q., Shivachandra SB, Zhang Z, Rao VB. 2007. Assembly of the small outer capsid protein, Soc, on bacteriophage T4: A novel system for high density display of multiple large anthrax toxins and foreign proteins on phage capsid. J Mol Biol 370: 1006-1019.
37. Lindner T., Kolmar H, Haberkorn U, Mier W. 2011. DNA libraries for the construction of phage libraries: Statistical and structural requirements and synthetic methods. Molecules 16: 1625-1641.
38. Liu M., Deora R, Doulatov SR, Gingery M, Eiserling FA, Preston A., Maskell DJ, Simons RW, Cotter PA, Parkhill J, et al. 2002. Reverse transcriptase-mediated tropism switching in Bordetella bacteriophage. Science 295: 2091-2094.
39. Loeffler J.M., Nelson D, Fischetti VA. 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294: 2170-2172.
40. Loeffler J.M., Djurkovic S, Fischetti VA. 2003. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 71: 6199-6204.
41. Loessner M.J., Kramer K, Ebel F, Scherer S. 2002. C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. Mol Microbiol 44: 335-349.
42. Lukacik P., Barnard TJ, KellerPW, Chaturvedi KS, Seddiki N, Fairman J.W., Noinaj N, Kirby TL, Henderson JP, Steven AC, et al. 2012. Proc Natl Acad Sci 109: 9857-9862.
43. Manoutcharian K., Terrazas LI, Gevorkian G, Acero G, Petrossian P, Rodriguez M, Govezensky T. 1999. Phage-displayed T-cell epitope grafted into immunoglobulin heavy-chain complementarity-determining regions: An effective vaccine design tested in murine cysticercosis. Infect Immun 67: 4764-4770.
44. Manoutcharian K., Diaz-Orea A, Gevorkian G, Fragoso G, Acero G., Gonzalez E, De Aluja A, Villalobos N, Gomez-Conde E., Sciutto E. 2004. Recombinant bacteriophagebased multiepitope vaccine against Taenia solium pig cysticercosis. Vet Immunol Immunopathol 99: 11-24.
45. March J.B., Clark JR, Jepson CD. 2004. Genetic immunisation against hepatitis B using whole bacteriophage λ particles. Vaccine 22: 1666-1671.
46. Marino G., Ferrarini V, Giardini S, Biavati B. 2003. Use of lysozyme for treatment of bacterial contamination in in vitro shoot cultures of fruit plants. In Vitro Cell Dev Biol 39: 327-331.
47. Markland W., Roberts BL, Saxena MJ, Guterman SK, Ladner RC. 1991. Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13. Gene 109: 13-19.
48. Mason K.A., Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, Whisnant JK, Milas L. 2005. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 11: 361-369.
49. Merril C.R., Geier MR, Petricciani JC. 1971. Bacterial virus gene expression in human cells. Nature 233: 398-400.
50. Merril C.R., Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S. 1996. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci 93: 3188-3192.
51. Merril C.R., Scholl D, Adhya SL. 2003. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2: 489-497.
52. Merril C.R., Scholl D, Adhya S. 2006. The bacteriophage. Oxford University Press, London.
53. Mikawa Y.G., Maruyama IN, Brenner S. 1996. Surface display of proteins on bacteriophage λ heads. J Mol Biol 262: 21-30.
54. Needham J. 1999. Science and civilisation in China. Cambridge University Press, Cambridge.
55. Nelson D., Loomis L, Fischetti VA. 2001. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci 98: 4107-4112.
56. O'Hagan DT, Rappuoli R. 2004. Novel approaches to vaccine delivery. Pharm Res 21: 1519-1530.
57. Pacheco S., Gomez I, Sato R, Bravo A, Soberon M. 2006. Functional display of Bacillus thuringiensis Cry1Ac toxin on T7 phage. J Invertebr Pathol 92: 45-49.
58. Paul V.D., Sundarrajan S, Rajagopalan SS, Hariharan S, Kempashanaiah N, Padmanabhan S, Sriram B, Ramachandran J. 2011. Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection. BMC Microbiol 11: 195.
59. Pauwels K., Gijsbers R, Toelen J, Schambach A, Willard-Gallo K, Verheust C, Debyser Z, Herman P. 2009. State-of-theart lentiviral vectors for research use: Risk assessment and biosafety recommendations. Curr Gene Ther 9: 459-474.
60. Petrovsky N., Aguilar JC. 2004. Vaccine adjuvants: Current state and future trends. Immunol Cell Biol 82: 488-496.
61. Pouillot F., Chomton M, Blois H, Courroux C, Noelig J, Bidet P, Bingen E, Bonacorsi S. 2012. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother 56: 3568-3575.
62. Ren Z., Black LW. 1998. Phage T4 SOC and HOC display of biologically active, full-length proteins on the viral capsid. Gene 215: 439-444.
63. Ren Z.J., Lewis GK, Wingfield PT, Locke EG, Steven AC, Black LW. 1996. Phage display of intact domains at high copy number: A system based on SOC, the small outer capsid protein of bacteriophage T4. Protein Sci 5: 1833-1843.
64. Ren Z.J., Baumann RG, Black LW. 1997. Cloning of linear DNAs in vivo by overexpressed T4 DNA ligase: Construction of a T4 phage hoc gene display vector. Gene 195: 303-311.
65. Riedel S. 2005. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 18: 21-25.
66. Sandmeier H. 1994. Acquisition and rearrangement of sequence motifs in the evolution of bacteriophage tail fibres. Mol Microbiol 12: 343-350.
67. Savinov S.N., Austin DJ. 2001. The cloning of human genes using cDNA phage display and small-molecule chemical probes. Comb Chem High T Scr 4: 593-597.
68. Sche P.P., McKenzie KM, White JD, Austin DJ. 2001. Corrigendum to: "Display cloning: Functional identification of natural product receptors using cDNA-phage display" [Chemistry & Biology 6 (1999) 707-716]. Chem Biol 8: 399-400.
69. SchollD, Rogers S, Adhya S, Merril CR. 2001. Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli. J Virol 75: 2509-2515.
70. Smith GP. 1985. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 228: 1315-1317.
71. Smith H.W., Huggins MB. 1982. Successful treatment of experimental Escherichia coli infections in mice using phage: Its general superiority over antibiotics. J Gen Microbiol 128: 307-318.
72. Sneade W. 2005. Drug discovery: A history. Wiley-Interscience, Hoboken, NJ.
73. Sulakvelidze A., Alavidze Z, Morris JG Jr. 2001. Bacteriophage therapy. Antimicrob Agents Chemother 45: 649-659.
74. Summers WC. 1999. Félix Herelle and the origins of molecular biology. Yale University Press, New Haven and London.
75. Tizard IR. 1984. Immunology: An introduction. Cengage Learning, Stamford, CT.
76. Verheust C., Pauwels K, Mahillon JD, Helinski R, Herman P. 2010. Contained use of bacteriophages: Risk assessment and biosafety recommendations. Appl Biosafety 15: 32-44.
77. Vitiello C.L., Merril CR, Adhya S. 2005. An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold. Virus Res 114: 101-103.
78. Waite J.G., Daeschel MA. 2007. Contribution of wine components to inactivation of food-borne pathogens. J Food Sci 72: M286-M291.
79. Wang I.N., Deaton J, Young R. 2003. Sizing the holin lesion with an endolysin-β-galactosidase fusion. J Bacteriol 185: 779-787.
80. Zanghi C.N., Sapinoro R, Bradel-Tretheway B, Dewhurst S. 2007. Atractable method for simultaneous modifications to the head and tail of bacteriophage λ and its application to enhancing phage-mediated gene delivery. Nucleic Acids Res 35: e59.
81. Zuercher A.W., Miescher SM, Vogel M, Rudolf MP, Stadler MB, Stadler BM. 2000. Oral anti-IgE immunization with epitope-displaying phage. Eur J Immunol 30: 128-135.